Clinical categorization algorithm (CLICAL) and machine learning approach (SRF-CLICAL) to predict clinical benefit to immunotherapy in metastatic melanoma …
G Madonna, GV Masucci, M Capone, D Mallardo… - Cancers, 2021 - mdpi.com
Simple Summary Immune checkpoint inhibitors have improved the prognosis for patients
with advanced melanoma. Despite the recent success of immunotherapy, many patients still
do not benefit from these treatments, and their real-life application may yield different
outcomes compared to the advantage presented in clinical trials. There is therefore a need
to select patients who can really benefit from these treatments. We have focused our study
on a real-life retrospective analysis of metastatic melanoma patients treated with …
with advanced melanoma. Despite the recent success of immunotherapy, many patients still
do not benefit from these treatments, and their real-life application may yield different
outcomes compared to the advantage presented in clinical trials. There is therefore a need
to select patients who can really benefit from these treatments. We have focused our study
on a real-life retrospective analysis of metastatic melanoma patients treated with …
[PDF][PDF] Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic …
G Madonna, GV Masucci, M Capone, D Mallardo… - 2021 - academia.edu
The real-life application of immune checkpoint inhibitors (ICIs) may yield different outcomes
compared to the benefit presented in clinical trials. For this reason, there is a need to define
the group of patients that may benefit from treatment. We retrospectively investigated 578
metastatic melanoma patients treated with ICIs at the Istituto Nazionale Tumori IRCCS
Fondazione “G. Pascale” of Napoli, Italy (INT-NA). To compare patients' clinical variables (ie,
age, lactate dehydrogenase (LDH), neutrophil–lymphocyte ratio (NLR), eosinophil, BRAF …
compared to the benefit presented in clinical trials. For this reason, there is a need to define
the group of patients that may benefit from treatment. We retrospectively investigated 578
metastatic melanoma patients treated with ICIs at the Istituto Nazionale Tumori IRCCS
Fondazione “G. Pascale” of Napoli, Italy (INT-NA). To compare patients' clinical variables (ie,
age, lactate dehydrogenase (LDH), neutrophil–lymphocyte ratio (NLR), eosinophil, BRAF …
以上显示的是最相近的搜索结果。 查看全部搜索结果